Vaccine

 

Recently published results from a controlled, randomised trial in UK concluded that concomitant vaccination with one of two SARS-CoV-2 vaccines (ChAdOx1 or BNT162b2) plus an age-appropriate influenza vaccine raised no safety concerns and preserves antibody responses to both vaccines. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02329-1/fulltext

 

Available vaccines in Europe 

https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/types-of-seasonal-influenza-vaccine

 

Vaccine composition

 

On 25 February 2022, WHO published recommendations for the components of influenza vaccines for use in the 2022-2023 northern hemisphere influenza season:

 

The WHO recommends that quadrivalent vaccines for use in the 2022-2023 influenza season in the northern hemisphere contain the following:

 

Egg-based Vaccines

 

          an A/Victoria/2570/2019 (H1N1)pdm09-like virus;

          an A/Darwin/9/2021 (H3N2)-like virus;

          a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and

          a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

 

Cell culture- or recombinant-based Vaccines

 

          an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;

          an A/Darwin/6/2021 (H3N2)-like virus;

          a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and

          a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

 

The WHO recommends that trivalent vaccines for use in the 2022-2023 influenza season in the northern hemisphere contain the following:

 

Egg-based vaccines

 

          an A/Victoria/2570/2019 (H1N1)pdm09-like virus;

          an A/Darwin/9/2021 (H3N2)-like virus; and

          a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

 

Cell culture- or recombinant-based vaccines

 

          an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;

          an A/Darwin/6/2021 (H3N2)-like virus; and

          a B/Austria/1359417/2021 (B/Victoria lineage)-like virus

 

On 23 September 2022, WHO published recommendations for the components of influenza vaccines for use in the 2023 southern hemisphere influenza season:

 

Egg-based Vaccines

 

          an A/Sydney/5/2021 (H1N1)pdm09-like virus;

          an A/Darwin/9/2021 (H3N2)-like virus;

          a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and

          a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

 

Cell- or recombinant-based Vaccines

 

          an A/Sydney/5/2021 (H1N1)pdm09-like virus;

          an A/Darwin/6/2021 (H3N2)-like virus;

          a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and

          a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

 

It is recommended that trivalent influenza vaccines for use in the 2023 southern hemisphere influenza season contain the following:

 

Egg-based vaccines

 

          an A/Sydney/5/2021 (H1N1)pdm09-like virus;

          an A/Darwin/9/2021 (H3N2)-like virus; and

          a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

 

Cell- or Recombinant-based vaccines

 

          an A/Sydney/5/2021 (H1N1)pdm09-like virus;

          an A/Darwin/6/2021 (H3N2)-like virus; and

          a B/Austria/1359417/2021 (B/Victoria lineage)-like virus

 

The full report is published here.